Truist downgraded Merus (MRUS) to Hold from Buy with a price target of $97, up from $88, following the company announcing it accepted Genmab’s (GMAB) bid at “a nice premium.” The firm thinks the deal terms are “favorable, all things considered,” the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRUS: